155 related articles for article (PubMed ID: 9826227)
1. Effect of catechol-O-methyltransferase inhibition on brain uptake of [18F]fluorodopa: implications for compartmental modelling and clinical usefulness.
Léger G; Gjedde A; Kuwabara H; Guttman M; Cumming P
Synapse; 1998 Dec; 30(4):351-61. PubMed ID: 9826227
[TBL] [Abstract][Full Text] [Related]
2. Cerebral 6-[18F]fluoro-L-DOPA uptake in rhesus monkey: pharmacological influence of aromatic amino acid decarboxylase (AAAD) and catechol-O-methyltransferase (COMT) inhibition.
Psylla M; Günther I; Antonini A; Vontobel P; Reist HW; Zollinger A; Leenders KL
Brain Res; 1997 Aug; 767(1):45-54. PubMed ID: 9365014
[TBL] [Abstract][Full Text] [Related]
3. Fluorodopa positron emission tomography with an inhibitor of catechol-O-methyltransferase: effect of the plasma 3-O-methyldopa fraction on data analysis.
Ishikawa T; Dhawan V; Chaly T; Robeson W; Belakhlef A; Mandel F; Dahl R; Margouleff C; Eidelberg D
J Cereb Blood Flow Metab; 1996 Sep; 16(5):854-63. PubMed ID: 8784230
[TBL] [Abstract][Full Text] [Related]
4. Striatal 6-[18F]fluorodopa accumulation after combined inhibition of peripheral catechol-O-methyltransferase and monoamine oxidase type B: differing response in relation to presynaptic dopaminergic dysfunction.
Ruottinen HM; Rinne JO; Oikonen VJ; Bergman JR; Haaparanta MT; Solin OH; Ruotsalainen UH; Rinne UK
Synapse; 1997 Dec; 27(4):336-46. PubMed ID: 9372556
[TBL] [Abstract][Full Text] [Related]
5. Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms.
Cumming P; Gjedde A
Synapse; 1998 May; 29(1):37-61. PubMed ID: 9552174
[TBL] [Abstract][Full Text] [Related]
6. 6-[18F]fluoro-L-dihydroxyphenylalanine metabolism and positron emission tomography after catechol-O-methyltransferase inhibition in normal and hemiparkinsonian monkeys.
Miletich RS; Comi G; Bankiewicz K; Plunkett R; Adams R; Di Chiro G; Kopin IJ
Brain Res; 1993 Oct; 626(1-2):1-13. PubMed ID: 8281420
[TBL] [Abstract][Full Text] [Related]
7. Striatal [18F]fluorodopa utilization after COMT inhibition with entacapone studied with PET in advanced Parkinson's disease.
Ruottinen HM; Rinne JO; Ruotsalainen UH; Bergman JR; Oikonen VJ; Haaparanta MT; Solin OH; Laihinen AO; Rinne UK
J Neural Transm Park Dis Dement Sect; 1995; 10(2-3):91-106. PubMed ID: 9620057
[TBL] [Abstract][Full Text] [Related]
8. The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease.
Sawle GV; Burn DJ; Morrish PK; Lammertsma AA; Snow BJ; Luthra S; Osman S; Brooks DJ
Neurology; 1994 Jul; 44(7):1292-7. PubMed ID: 8035933
[TBL] [Abstract][Full Text] [Related]
9. Positron emission tomography in drug evaluation: influence of three different catechol-O-methyltransferase inhibitors on metabolism of [NCA] 6-[18F]fluoro-L-dopa in rhesus monkey.
Günther I; Psylla M; Reddy GN; Antonini A; Vontobel P; Reist HW; Zollinger A; Nickles RJ; Beer HF; Schubiger PA
Nucl Med Biol; 1995 Oct; 22(7):921-7. PubMed ID: 8547890
[TBL] [Abstract][Full Text] [Related]
10. Effects of monoamine oxidase and catechol-O-methyltransferase inhibition on dopamine turnover: a PET study with 6-[18F]L-DOPA.
Doudet DJ; Chan GL; Holden JE; Pate BD; Morrison KS; Calne DB; Ruth TJ
Eur J Pharmacol; 1997 Sep; 334(1):31-8. PubMed ID: 9346324
[TBL] [Abstract][Full Text] [Related]
11. Cerebral 6-[(18)F]fluoro-L-DOPA (FDOPA) metabolism in pig studied by positron emission tomography.
Danielsen EH; Smith DF; Gee AD; Venkatachalam TK; Hansen SB; Hermansen F; Gjedde A; Cumming P
Synapse; 1999 Sep; 33(4):247-58. PubMed ID: 10421705
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and evaluation of an 18F-labeled dopa prodrug as a PET tracer for studying brain dopamine metabolism.
Ishiwata K; Shinoda M; Ishii S; Nozaki T; Senda M
Nucl Med Biol; 1996 Apr; 23(3):295-301. PubMed ID: 8782240
[TBL] [Abstract][Full Text] [Related]
13. Effect of partial volume correction on estimates of the influx and cerebral metabolism of 6-[(18)F]fluoro-L-dopa studied with PET in normal control and Parkinson's disease subjects.
Rousset OG; Deep P; Kuwabara H; Evans AC; Gjedde AH; Cumming P
Synapse; 2000 Aug; 37(2):81-9. PubMed ID: 10881028
[TBL] [Abstract][Full Text] [Related]
14. Peripheral and central inhibitors of catechol-O-methyl transferase: effects on liver and brain COMT activity and L-DOPA metabolism.
Brannan T; Prikhojan A; Yahr MD
J Neural Transm (Vienna); 1997; 104(1):77-87. PubMed ID: 9085195
[TBL] [Abstract][Full Text] [Related]
15. General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase.
Kaakkola S; Gordin A; Männistö PT
Gen Pharmacol; 1994 Sep; 25(5):813-24. PubMed ID: 7835624
[TBL] [Abstract][Full Text] [Related]
16. Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa.
Guttman M; Léger G; Reches A; Evans A; Kuwabara H; Cedarbaum JM; Gjedde A
Mov Disord; 1993 Jul; 8(3):298-304. PubMed ID: 8341294
[TBL] [Abstract][Full Text] [Related]
17. Graphical analysis of 6-fluoro-L-dopa trapping: effect of inhibition of catechol-O-methyltransferase.
Holden JE; Doudet D; Endres CJ; Chan GL; Morrison KS; Vingerhoets FJ; Snow BJ; Pate BD; Sossi V; Buckley KR; Ruth TJ
J Nucl Med; 1997 Oct; 38(10):1568-74. PubMed ID: 9379194
[TBL] [Abstract][Full Text] [Related]
18. Effect of a novel catechol-O-methyltransferase inhibitor, nitecapone, on the metabolism of L-dopa in healthy volunteers.
Kaakkola S; Gordin A; Järvinen M; Wikberg T; Schultz E; Nissinen E; Pentikäinen PJ; Rita H
Clin Neuropharmacol; 1990 Oct; 13(5):436-47. PubMed ID: 2272023
[TBL] [Abstract][Full Text] [Related]
19. [18F]-6-fluorodopa PET scanning in Parkinson's disease after selective COMT inhibition with nitecapone (OR-462).
Laihinen A; Rinne JO; Rinne UK; Haaparanta M; Ruotsalainen U; Bergman J; Solin O
Neurology; 1992 Jan; 42(1):199-203. PubMed ID: 1734304
[TBL] [Abstract][Full Text] [Related]
20. Detection of response to COMT inhibition in FDOPA PET in advanced Parkinson's disease requires prolonged imaging.
Ruottinen HM; Niinivirta M; Bergman J; Oikonen V; Solin O; Eskola O; Eronen E; Sonninen P; Rinne UK
Synapse; 2001 Apr; 40(1):19-26. PubMed ID: 11170218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
